Uncommon metachronous multiple sites recurrences of metastatic osteosarcoma cured by surgery: a case report

References

• Anderson ME. Update on survival in osteosarcoma. Orthop Clin North Am. 2016;47(1):283–292. doi: 10.1016/j.ocl.2015.08.022.
   PubMed Web of Science ®Google Scholar
• Mialou V, Philip T, Kalifa C, et al. Metastatic osteosarcoma at diagnosis: prognostic factors and long-term outcome–the French pediatric experience. Cancer. 2005; 104(5):1100–1109. doi: 10.1002/cncr.21263.
   PubMed Web of Science ®Google Scholar
• Piperno-Neumann S, Le Deley MC, Rédini F, et al. Zoledronate in combination with chemotherapy and surgery to treat osteosarcoma (OS2006): a randomised, multicentre, open-label, phase 3 trial. Lancet Oncol. 2016;17(8):1070–1080. doi: 10.1016/S1470-2045(16)30096-1.
   PubMed Web of Science ®Google Scholar
• Marina NM, Smeland S, Bielack SS, et al. Comparison of MAPIE versus MAP in patients with a poor response to preoperative chemotherapy for newly diagnosed high-grade osteosarcoma (EURAMOS-1): an open-label, international, randomised controlled trial. Lancet Oncol. 2016;17(10):1396–1408. doi: 10.1016/S1470-2045(16)30214-5.
   PubMed Web of Science ®Google Scholar
• Spraker-Perlman HL, Barkauskas DA, Krailo MD, et al. Factors influencing survival after recurrence in osteosarcoma: a report from the children’s oncology group. Pediatr Blood Cancer. 2019;66(1):e27444. doi: 10.1002/pbc.27444.
   PubMed Web of Science ®Google Scholar
• Thebault E, Piperno-Neumann S, Tran D, et al. Successive osteosarcoma relapses after the first line O2006/sarcome-09 trial: what can we learn for further phase-II trials? Cancers. 2021; 13(7):1683. doi: 10.3390/cancers13071683.
   PubMed Web of Science ®Google Scholar
• Kempf-Bielack B, Bielack SS, Jürgens H, et al. Osteosarcoma relapse after combined modality therapy: an analysis of unselected patients in the cooperative osteosarcoma study group (COSS). J Clin Oncol. 2005;23(3):559–568. doi: 10.1200/JCO.2005.04.063.
   PubMed Web of Science ®Google Scholar
• Bielack SS, Kempf-Bielack B, Branscheid D, et al. Second and subsequent recurrences of osteosarcoma: presentation, treatment, and outcomes of 249 consecutive cooperative osteosarcoma study group patients. J Clin Oncol. 2009;27(4):557–565. doi: 10.1200/JCO.2008.16.2305.
   PubMed Web of Science ®Google Scholar
• Tamamyan G, Dominkus M, Lang S, et al. Multiple relapses in high-grade osteosarcoma: when to stop aggressive therapy? Pediatr Blood Cancer. 2015;62(3):529–530. doi: 10.1002/pbc.25360.
   PubMed Web of Science ®Google Scholar
• Crompton BD, Goldsby RE, Weinberg VK, et al. Survival after recurrence of osteosarcoma: a 20-year experience at a single institution. Pediatr Blood Cancer. 2006;47(3):255–259. doi: 10.1002/pbc.20580.
   PubMed Web of Science ®Google Scholar
• Le Deley MC, Guinebretière JM, Gentet JC, et al. SFOP OS94: a randomised trial comparing preoperative high-dose methotrexate plus doxorubicin to high-dose methotrexate plus etoposide and ifosfamide in osteosarcoma patients. Eur J Cancer. 2007; 43(4):752–761. doi: 10.1016/j.ejca.2006.10.023.
   PubMed Web of Science ®Google Scholar
• Bielack SS, Kempf-Bielack B, Delling G, et al. Prognostic factors in high-grade osteosarcoma of the extremities or trunk: an analysis of 1,702 patients treated on neoadjuvant cooperative steosarcoma study group protocols. J Clin Oncol. 2002;20(3):776–790. doi: 10.1200/JCO.2002.20.3.776.
   PubMed Web of Science ®Google Scholar
• Bacci G, Rocca M, Salone M, et al. High grade osteosarcoma of the extremities with lung metastases at presentation: treatment with neoadjuvant chemotherapy and simultaneous resection of primary and metastatic lesions. J Surg Oncol. 2008;98(6):415–420. doi: 10.1002/jso.21140.
   PubMed Web of Science ®Google Scholar
• Buddingh EP, Anninga JK, Versteegh MIM, et al. Prognostic factors in pulmonary metastasized high-grade osteosarcoma. Pediatr Blood Cancer. 2010; 54(2):216–221. doi: 10.1002/pbc.22293.
   PubMed Web of Science ®Google Scholar
• Daw NC, Chou AJ, Jaffe N, et al. Recurrent osteosarcoma with a single pulmonary metastasis: a multi-institutional review. Br J Cancer. 2015; 112(2):278–282. doi: 10.1038/bjc.2014.585.
   PubMed Web of Science ®Google Scholar
• Tirtei E, Asaftei SD, Manicone R, et al. Survival after second and subsequent recurrences in osteosarcoma: a retrospective multicenter analysis. Tumori. 2018;104(3):202–206. doi: 10.1177/0300891617753257.
   PubMed Web of Science ®Google Scholar
• Leary SE, Wozniak AW, Billups CA, et al. Survival of pediatric patients after relapsed osteosarcoma: the St. Jude Children’s Research Hospital experience. Cancer. 2013;119(14):2645–2653. doi: 10.1002/cncr.28111.
   PubMed Web of Science ®Google Scholar
• Bacci G, Briccoli A, Longhi A, et al. Treatment and outcome of recurrent osteosarcoma: experience at Rizzoli in 235 patients initially treated with neoadjuvant chemotherapy. Acta Oncol. 2005;44(7):748–755. doi: 10.1080/02841860500327503.
   PubMed Web of Science ®Google Scholar
• Smolle MA, Szkandera J, Andreou D, et al. Treatment options in unresectable soft tissue and bone sarcoma of the extremities and pelvis – a systematic literature review. EFORT Open Rev. 2020;5(11):799–814. doi: 10.1302/2058-5241.5.200069.
   PubMed Web of Science ®Google Scholar
• Salvati M, D'Elia A, Frati A, et al. Sarcoma metastatic to the brain: a series of 35 cases and considerations from 27 years of experience. J Neurooncol. 2010;98(3):373–377. doi: 10.1007/s11060-009-0085-0.
   PubMed Web of Science ®Google Scholar
• Shweikeh F, Bukavina L, Saeed K, et al. Brain metastasis in bone and soft tissue cancers: a review of incidence, interventions and outcomes. Sarcoma. 2014;2014:475175. doi: 10.1155/2014/475175.
   PubMedGoogle Scholar
• Nieto-Coronel MT, López-Vásquez AD, Marroquín-Flores D, et al. Central nervous system metastasis from osteosarcoma: case report and literature review. Rep Pract Oncol Radiother. 2018; 23(4):266–269. doi: 10.1016/j.rpor.2018.06.003.
   PubMedGoogle Scholar
• Rejin K, Aykan OA, Omer G, et al. Intra-abdominal metastasis in osteosarcoma: survey and literature review. Pediatr Hematol Oncol. 2011; 28(7):609–615. doi: 10.3109/08880018.2011.590959.
   PubMed Web of Science ®Google Scholar
• Italiano A, Mir O, Mathoulin-Pelissier S, et al. Cabozantinib in patients with advanced ewing sarcoma or osteosarcoma (CABONE): a multicentre, single-arm, phase 2 trial. Lancet Oncol. 2020; 21(3):446–455. doi: 10.1016/S1470-2045(19)30825-3.
   PubMed Web of Science ®Google Scholar
• Duffaud F, Mir O, Boudou-Rouquette P, et al. Efficacy and safety of regorafenib in adult patients with metastatic osteosarcoma: a non-comparative, randomized, double-blind, placebo-controlled, phase 2 study. Lancet Oncol. 2019; 20(1):120–133. doi: 10.1016/S1470-2045(18)30742-3.
   PubMed Web of Science ®Google Scholar
• Harrison DJ, Geller DS, Gill JD, et al. Current and future therapeutic approaches for osteosarcoma. Expert Rev Anticancer Ther. 2018;18(1):39–50. doi: 10.1080/14737140.2018.1413939.
   PubMed Web of Science ®Google Scholar